Polyinosinic-polycytidylic acid (sodium)
CAT:
804-HY-135748-04
Size:
50 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Polyinosinic-polycytidylic acid (sodium)
- CAS Number: 42424-50-0
- UNSPSC Description: Polyinosinic-polycytidylic acid (Poly(I:C)) sodium is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid sodium can directly trigger cancer cells to undergo apoptosis[1][2].
- Target Antigen: Apoptosis; Toll-like Receptor (TLR)
- Type: Reference compound
- Related Pathways: Apoptosis;Immunology/Inflammation
- Field of Research: Cancer; Inflammation/Immunology
- Assay Protocol: https://www.medchemexpress.com/polyinosinic-polycytidylic-acid-sodium.html
- Smiles: O[C@H]1[C@@H](O[C@H](COP(O)(O)=O)[C@H]1O)N2C3=C(C(NC=N3)=O)N=C2.O[C@H]4[C@H](N5C(N=C(N)C=C5)=O)O[C@H](COP(O)(O)=O)[C@H]4O.[x].[x].[Na].[x]
- References & Citations: [1]Besch R, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest. 2009 Aug;119(8):2399-411.|[2]Cheng YS, et al. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther. 2010 Dec 15;10(12):1219-23.|[3]Robert Field, et al. Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun. 2010 Aug;24(6):996-1007.Adv Funct Mater. 29 August 2022.|Liver Int. 2022 Oct 17.|Mol Ther Oncolytics. 25 August 2022.|Phytomedicine. 2021, 153495.|SSRN. 2021 Apr 26.|Autophagy. 2024 May 18.|Biochem Biophys Res Commun. 2024 Feb 15, 149661.|bioRxiv. 2024 Dec 8:2024.12.07.627371.|bioRxiv. 2024 September 23.|Cancer Immunol Res. 2024 Jul 11.|Cancer Med. 2023 Jun 7.|Chem Biol Drug Des. 2023 Nov;102(5):1110-1120.|Chem Eng J. 2021 Aug 15;418:129392.|Clin Cosmet Investig Dermatol. 2024 May 14:17:1093-1105.|Clin Transl Med. 2024 Sep;14(9):e70027.|Curr Microbiol. 2024 Aug 6;81(9):296.|FASEB J. 2024 Mar 31.|Res Sq. 2024 Nov 14.|SSRN. 2023 Apr 29.|Vet Res. 2024 Sep 27;55(1):115.|Virol Sin. 2023 Aug 24;S1995-820X(23)00104-9.|Virol Sin. 2023 May 2;S1995-820X(23)00048-2.
- Shipping Conditions: Blue Ice